Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of Schizophrenia

Trial Profile

A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2019

At a glance

  • Drugs Cariprazine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Gedeon Richter
  • Most Recent Events

    • 16 Apr 2019 Results of new post hoc analysis (n=454) was presented during the 27th psychiatry congress of the European Psychiatric Association (EPA) in Warsaw, Poland.
    • 09 May 2018 Results of post hoc analysis (n=456; ITT) assessing the consistency of the effect of cariprazine on negative symptoms of schizophrenia using data from this study, presented at the 171st Annual Meeting of the American Psychiatric Association.
    • 22 Sep 2017 According to an Allergan media release, Cariprazine is approved in Europe for the treatment of schizophrenia, the approval included data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top